{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:38:41Z","timestamp":1793367521655,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41585-026-01150-x","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:00:31Z","timestamp":1777982431000},"page":"705-707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Managing patients with recurrent prostate cancer who refuse ADT"],"prefix":"10.1038","volume":"23","author":[{"given":"Kerry R.","family":"Schaffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-5100","authenticated-orcid":false,"given":"Mark C.","family":"Markowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"1150_CR1","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.23.00323","volume":"41","author":"HD McManus","year":"2023","unstructured":"McManus, H. D. & Armstrong, A. J. The past, present, and future of treatment intensification for metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 41, 3576\u20133579 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1150_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2024.01.011","volume":"62","author":"K Beyer","year":"2024","unstructured":"Beyer, K. et al. How can we improve patient-clinician communication for men diagnosed with prostate cancer? Eur. Urol. Open Sci. 62, 1\u20137 (2024).","journal-title":"Eur. Urol. Open Sci."},{"key":"1150_CR3","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.2147\/PPA.S271620","volume":"14","author":"LB Oswald","year":"2020","unstructured":"Oswald, L. B. et al. What do men with metastatic prostate cancer consider when making treatment decisions? A mixed-methods study. Patient Prefer. Adherence 14, 1949\u20131959 (2020).","journal-title":"Patient Prefer. Adherence"},{"key":"1150_CR4","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.jsxm.2022.08.197","volume":"19","author":"D Wittmann","year":"2022","unstructured":"Wittmann, D. et al. Guidelines for sexual health care for prostate cancer patients: recommendations of an international panel. J. Sex. Med. 19, 1655\u20131669 (2022).","journal-title":"J. Sex. Med."},{"key":"1150_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.clgc.2019.08.002","volume":"17","author":"MC Markowski","year":"2019","unstructured":"Markowski, M. C. et al. PSA doubling time and absolute PSA predict metastasis-free survival in men with biochemically recurrent prostate cancer after radical prostatectomy. Clin. Genitourin. Cancer 17, 470\u2013475.e1 (2019).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1150_CR6","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost, P. et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J. Clin. Oncol. 36, 446\u2013453 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1150_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips, R. et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 6, 650\u2013659 (2020).","journal-title":"JAMA Oncol."},{"key":"1150_CR8","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland, S. J. et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N. Engl. J. Med. 389, 1453\u20131465 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1150_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.eururo.2025.02.006","volume":"87","author":"SJ Freedland","year":"2025","unstructured":"Freedland, S. J. et al. Effects of enzalutamide on the sexual activity of patients with biochemically recurrent prostate cancer: a post hoc analysis of patient-reported outcomes in the EMBARK study. Eur. Urol. 87, 507\u2013511 (2025).","journal-title":"Eur. Urol."},{"key":"1150_CR10","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0090-4295(99)80356-2","volume":"46","author":"G Chodak","year":"1995","unstructured":"Chodak, G. et al. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 46, 849\u2013855 (1995).","journal-title":"Urology"}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01150-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01150-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01150-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:01:40Z","timestamp":1793365300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01150-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1038\/s41585-026-01150-x","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"5 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}